Search

Legend Biotech Corp ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

18.55 -3.99

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

18.5

Max

18.66

Pagrindiniai rodikliai

By Trading Economics

Pajamos

88M

33M

Pardavimai

82M

388M

Pelnas, tenkantis vienai akcijai

0.09

Pelno marža

8.568

Darbuotojai

3,200

EBITDA

92M

60M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+144.54% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-11

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-375M

3.6B

Ankstesnė atidarymo kaina

22.54

Ankstesnė uždarymo kaina

18.55

Naujienos nuotaikos

By Acuity

43%

57%

67 / 340 reitingas Healthcare

Legend Biotech Corp ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-10-02 22:50; UTC

Legend Biotech Corp is seeing a notable increase in after-market trading, driven by strong upward momentum following Friday's close.

2026-10-01 20:07; UTC

News

Legend Biotech Corp's shares fell sharply on Thursday, following a broader market decline, despite earlier rebounding from a session low.

2026-09-30 20:01; UTC

News

HC Wainwright reaffirmed its Buy rating on Legend Biotech and maintained a $65 price target, contributing to a sharp rise in shares during the session.

2026-09-29 20:40; UTC

Legend Biotech Corp is rising in after-market trading, reflecting broader market strength despite economic data showing a cooling labor market and falling WTI crude prices.

2026-09-28 20:07; UTC

Event

Legend Biotech Corp announced five-year follow-up data from the CARTITUDE-2 study, but shares fell significantly from Friday's close and remain under pressure.

2026-09-25 22:01; UTC

Event

Legend Biotech Corp shares are trading modestly lower in after-market hours following the announcement of five-year follow-up data from the CARTITUDE-2 study.

2026-09-24 20:07; UTC

Legend Biotech Corp is advancing during the current trading session, gaining ground since Wednesday's close, despite trading below its 20-day moving average.

2026-09-23 23:01; UTC

Legend Biotech Corp is trading lower in after-market hours, following a decline since Wednesday's close and fluctuating near the lower end of its one-month range.

2026-09-21 20:06; UTC

Legend Biotech Corp is advancing, continuing its upward trajectory with notable gains today, despite remaining below its 20-day moving average.

2026-09-18 23:01; UTC

Legend Biotech Corp is advancing in after-market trading, showing a notable upward move since Friday's close, despite being below its 20-day moving average.

2026-09-17 23:46; UTC

Legend Biotech Corp saw a modest increase in after-market trading, though it remains significantly below its 20-day moving average.

2026-09-16 20:10; UTC

News

Legend Biotech Corp shares fell sharply today despite reporting second-quarter CARVYKTI sales of $657 million, marking the tenth consecutive session of declines.

2026-09-15 22:02; UTC

Legend Biotech shares were roughly flat in after-market hours, remaining significantly below their 20-day moving average after nine consecutive lower sessions.

2026-09-14 19:36; UTC

Shares of Legend Biotech Corp are lower today, continuing a broader trend. The stock remains significantly below its 20-day moving average.

2026-09-11 23:26; UTC

Legend Biotech Corp shares are higher in after-market trading, reflecting notable gains since Friday's close amid speculation about Federal Reserve interest rate hikes.

2026-09-09 20:07; UTC

Legend Biotech Corp shares are lower, continuing a trend of four consecutive daily declines. The stock remains below its 20-day moving average.

2026-09-08 23:06; UTC

Shares of Legend Biotech Corp. are higher in after-market trading, recovering from a recent decline that saw three consecutive lower closes.

2026-09-03 19:47; UTC

Shares of Legend Biotech Corp are lower today, despite earlier fluctuations that reached a session high. The stock remains above its 20-day moving average.

2026-09-02 20:03; UTC

News

Legend Biotech shares are higher as management discusses CARVYKTI's commercial rollout and plans to expand manufacturing capabilities at the Morgan Stanley Global Healthcare Conference.

2026-09-01 20:01; UTC

News

Legend Biotech will participate in the Morgan Stanley Global Healthcare Conference on September 15, 2026, as shares trade higher since Monday's close.

2026-08-31 22:16; UTC

Legend Biotech Corp shares are higher in after-market hours, reflecting a shift from recent higher daily closes amid broader market reactions to inflation comments from the Fed.

2026-08-28 20:07; UTC

Legend Biotech Corp shares are lower today, marking a fourth consecutive decline. Rising U.S. Treasury yields may be impacting investor sentiment.

2026-08-27 22:26; UTC

Legend Biotech Corp. shares are higher in after-market trading, gaining slightly since Thursday's close amid routine market fluctuations.

2026-08-26 23:11; UTC

Legend Biotech Corp shares are higher in after-market hours, reflecting the broader market's upward trend amid positive sentiment from major stocks.

2026-08-25 19:06; UTC

Shares of Legend Biotech Corp are higher today, remaining above their 20-day moving average amid positive market sentiment linked to falling oil prices.

2026-08-24 23:01; UTC

Legend Biotech Corp shares are higher in after-market trading, continuing a strong upward trend since Monday's close. The stock remains above its 20-day moving average.

2026-08-21 23:01; UTC

Legend Biotech Corp shares are higher in after-market trading, maintaining a position near the upper end of their one-month trading range.

2026-08-20 23:46; UTC

Legend Biotech Corp. shares are trading higher in after-market hours, diverging from broader market pressures amid rising crude oil prices and geopolitical tensions.

2026-08-19 23:01; UTC

Legend Biotech Corp shares are higher in after-market trading, showing notable strength and exceeding the 20-day moving average. No specific news was identified.

2026-08-18 20:03; UTC

Social Media

Legend Biotech Corp shares are higher today, buoyed by strong investor sentiment and analyst confidence in significant upside potential for the stock.

Akcijų palyginimas

Kainos pokytis

Legend Biotech Corp ADR Prognozė

Kainos tikslas

By TipRanks

144.54% į viršų

12 mėnesių prognozė

Vidutinis 45.411 USD  144.54%

Aukščiausias 74 USD

Žemiausias 24 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Legend Biotech Corp ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

5

Pirkti

4

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

67 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.